Stock Market - Sorry Vegans, I'm bullish on bulls |
- Sorry Vegans, I'm bullish on bulls
- Hmmmmm....
- Ain’t That The Truth
- Is there any other option? I only see a blue pill..
- Ivy League graduate students are drowning in debt up to $200K, yet earn as low as $30K two years after graduation
- I went all in on $VRME and bought more shares than the CEO of the company. He has around 80,000 shares, I'm at 128,600. Right now... I'm down like 70k lmao. Help! Hahaha
- Is it a side effect of Pandemic
- "Hey honey, did you buy the dip yesterday?"
- $275k club!!!
- The bull market in stocks may last up to five years — here are six reasons why
- ���� Charting, Chronologies, and More: Reasons I considered investing in the new GameStop (GME) ����
- Earnings Season Begins! Most Anticipated Earnings Releases for the week beginning July 12th, 2021
- Assault on Monopolies [Implications for FAANG]
- #afterhours 07/09
- Here is a Market Recap for today Friday, July 9, 2021. Please enjoy!
- P/E ratios in the S&P 500
- Bullish��
- Biogen Faces FDA Probe of Alzheimer’s Drug Approval; Stock Falls
- $XELA: GREAT NEWS! SHORT BORROW FEE RATE HAS INCREASED!!! WHICH MEANS A SHORT SQUEEZE IS GETTING CLOSER!
- Steve Cohen’s Bet on Melvin Leaves Point72 Trailing Hedge-Fund Peers
- Clov knowledge
- Any thoughts on when viacomcbs will make that recovery ? I think we all know its gonna happen but when ?
- $XELA, EXELA RANKS #1 for a Potential Short Squeeze!
- Jim Cramer 2nd Segment on Tether the ticking time bomb. Tether's commercial paper could be Chinese. Potentially damaging to short term credit markets. Cramers on the case.
- Wall Street Week Ahead for the trading week beginning July 12th, 2021
| Sorry Vegans, I'm bullish on bulls Posted: 09 Jul 2021 09:23 AM PDT
 | ||
| Posted: 09 Jul 2021 07:02 PM PDT
 | ||
| Posted: 09 Jul 2021 09:56 PM PDT
 | ||
| Is there any other option? I only see a blue pill.. Posted: 09 Jul 2021 06:02 PM PDT
 | ||
| Posted: 09 Jul 2021 05:37 PM PDT
 | ||
| Posted: 09 Jul 2021 02:19 PM PDT
 | ||
| Is it a side effect of Pandemic Posted: 09 Jul 2021 10:48 PM PDT
 | ||
| "Hey honey, did you buy the dip yesterday?" Posted: 09 Jul 2021 12:08 PM PDT
 | ||
| Posted: 09 Jul 2021 11:57 AM PDT So I just made it into the $275k club this week. Next stop $300k! I am 32 and started with nothing right out of college in 2010. I had a $100k divorce at 27. My annual income has ranged between $60k-$90k. How: I started putting money in index funds right from the start. Every month. Every pay check. In 2020 I started actively managing my own money. What I learned:
Get paid money to buy stocks you already want, at a price you want them at. And get paid to sell stocks you already want to sell at a price you want to sell them at. You can't lose. Who else is in a similar situation? What have you learned? [link] [comments]  | ||
| The bull market in stocks may last up to five years — here are six reasons why Posted: 09 Jul 2021 07:07 PM PDT
 | ||
| ���� Charting, Chronologies, and More: Reasons I considered investing in the new GameStop (GME) ���� Posted: 09 Jul 2021 10:23 AM PDT
 | ||
| Earnings Season Begins! Most Anticipated Earnings Releases for the week beginning July 12th, 2021 Posted: 09 Jul 2021 10:16 PM PDT
 | ||
| Assault on Monopolies [Implications for FAANG] Posted: 09 Jul 2021 08:00 PM PDT
 | ||
| Posted: 09 Jul 2021 09:45 PM PDT
 | ||
| Here is a Market Recap for today Friday, July 9, 2021. Please enjoy! Posted: 09 Jul 2021 02:01 PM PDT PsychoMarket Recap - Friday, July 9, 2021 The stock market pulled a remarkable turnaround today, shaking off yesterday's declines with the S&P 500 (SPY) rocketing to another record intraday high, led by the financial and energy sectors, which had been lagging as of late and continued strength in mega-cap tech stocks. It seems that after a brief flare up of concerns regarding the coronavirus delta variant and a potential acceleration of the timeline to taper quantitative easing in the US, fears have greatly tempered. At the time of writing, the Dow Jones (DIA) rose 1.27% while the Nasdaq (QQQ) rose 0.6% and is very slightly below it's all-time high. The Russell 2000 (IWM), which tracks the performance of small-caps, led the day, rising more than 2%. In recent weeks, market participants are increasingly trying to gauge if the surge we are seeing in the more contagious coronavirus delta variant will weigh on global growth rates. Yesterday, it seems concerns came to a head after the Japanese government made a last minute announcement that a state of emergency would be re-instituted across Tokyo and that all events would take place behind closed doors, with no spectators, walking back an earlier decision to allow locals to attend the games. The state of emergency will begin on Monday and run through Aug. 22, while the games are scheduled from July 23 to Aug. 8. On Wednesday, 16 days before the Opening Ceremony, the Tokyo Metropolitan Government reported 920 COVID cases, over 200 more than any other single-day total since May. On Thursday, it reported 896, the second-highest count since May. Other countries, like India and Brazil, are also dealing with an extremely worrying surge of cases. Even in the US, where roughly 50% of those eligible are fully vaccinated, the country is seeing a small surge in cases recently, with the delta variant accounting for 51.7% of all new infections, according to the CDC. According to reports, as of yesterday, only 16.8% of the Japanese population was vaccinated against the virus. In other news, in another move that raised concerns about the global growth rate, China's central bank signalled it will be cutting the amount of cash that banks must hold in reserve, a move that suggests the economic recovery in China may be slowing down. The People's Bank of China (PBOC) will reduce the reserve requirement ratio by 0.5 percentage point for most banks, according to a statement published Friday. That will unleash about 1 trillion yuan ($154 billion) of long-term liquidity into the economy and will be effective on July 15, the central bank said. The reduction was signaled earlier this week, when the State Council, China's equivalent of a cabinet, hinted the central bank would make more liquidity available to banks so they could lend to smaller firms hurt by rising costs. The timing and magnitude of the move, coming a week before second-quarter growth data, suggests worries about the economy's outlook and was a decisive shift away from policy tightening, which most, if not all, recovering economies are pursuing. Ken Cheung, Chief Asian Foreign Exchange Strategist at Mizuho, said "The PBOC came in broader and sooner than expected, highlighting the policy urgency to support the Chinese economy. Such firm easing measures could further fuel concern over China's growth outlook in the second half as well as the upcoming Q2 GDP figures in the coming week". Just to put into more familiar terms, this would be like if the Federal Reserve suddenly turned around and said rather than discussing tapering quantitative easing, it would instead propose pumping more money into the economy. While these global concerns did jitter the market yesterday, the impressive recovery in US equities underscores the remarkable strength of its economy, as the country continues reopening thanks to effective distribution of the vaccine, with 48% of the population fully vaccinated, according to the CDC. In my opinion, while the delta variant does pose a risk to global growth rates, and the market may react negatively to headlines about it, the foundations of the recovery in the US (i.e nation-wide reopening measures, a rapidly improving labor market, record earnings from companies, and a high level of savings among Americans) are very strong and will continue to underpin a bull market here. Highlights
"An investment in knowledge always pays the best interest." - Benjamin Franklin [link] [comments]  | ||
| Posted: 09 Jul 2021 02:15 AM PDT
 | ||
| Posted: 09 Jul 2021 09:19 AM PDT
 | ||
| Biogen Faces FDA Probe of Alzheimer’s Drug Approval; Stock Falls Posted: 09 Jul 2021 07:55 PM PDT Biogen Faces FDA Probe of Alzheimer's Drug Approval; Stock Falls (yahoo.com) Robert Langreth and Riley Griffin BIIB -2.95% (Bloomberg) -- The head of the U.S. Food and Drug Administration said she is seeking a federal investigation of the approval of the Biogen Inc. Alzheimer's disease drug Aduhelm, a highly unusual step that will increase scrutiny of a heavily criticized clearance. In a letter posted on Twitter, Janet Woodcock, the agency's acting commissioner, said she was requesting an independent review of whether any interactions between Biogen and FDA staff were inconsistent with the agency's policies and procedures. The inspector general for the Department of Health and Human Services would undertake the probe. Biogen shares were down 3.5% at 3:34 p.m. Friday in New York. Aduhelm was granted approval by the FDA last month over the objection of outside scientific advisers who had voted against the drug last November. The agency ordered Biogen to do an additional trial to confirm that the therapy benefits patients, and given nine years to produce data. Biogen has priced Aduhelm at $56,000 annually. In the letter, Woodcock said she had "tremendous confidence in the integrity" of the FDA staff, but said there were concerns over contacts between the agency and Biogen that may have occurred outside of the normal formal correspondence process. "It is critical that the events at issue be reviewed by an independent body," she wrote. A Biogen spokeswoman said that the company would cooperate with any inquiry into the Aduhelm review process. House Democrats are investigating the approval and pricing of Aduhelm, and senators have asked Finance Committee Chairman Ron Wyden to hold a hearing on the matter. Democratic Senator Joe Manchin, considered a crucial vote in the party's slim majority, blasted the approval and wrote President Joe Biden to request that someone other than Woodcock be chosen to be the agency's permanent commissioner. Frequent Meetings Big trials of Aduhelm that were halted by Biogen in 2019 produced contradictory results as to whether it slows cognitive decline. So the agency instead approved the drug under a special pathway that requires less data called accelerated approval. This possibility wasn't considered by the outside advisers who reviewed the drug's data in November 2020. Throughout 2019, after Biogen had said it had stopped its trials because the drug was unlikely to work, FDA officials held regular meetings with company executives, according to a person familiar with the matter. Billy Dunn, the director of the FDA's Office of Neuroscience, was central to the discussions. In the spring, Dunn met with Al Sandrock, who now serves as Biogen's head of research and development, at a medical conference in Philadelphia, according to the person, and the regulator suggested Biogen not abandon the candidate. FDA staffers later prepared a memo for a June 14, 2019, meeting with Biogen in which regulators and executives would discuss five different paths forward for Aduhelm, according to a person familiar with the matter. One of the pathways described in the memo included an accelerated approval, the person said. The memo said that another alternative was to stop all clinical studies if the parties were to conclude that the evidence showed Aduhelm didn't appear to work. FDA officials, however, said that option was off the table, according to the person, and proceeded to discuss alternatives. Representatives for the FDA didn't immediately respond to requests for comment. Dunn couldn't immediately be reached for comment. Some of the details of the meetings between company officials and the FDA were first reported by the news outlet Stat. Accelerated Pathway Five days later, in a meeting of Biogen's board of directors, the accelerated approval pathway was once again discussed, said the person. The consensus among Biogen executives was that it was more likely that the experimental drug could gain approval through other means, such as pursuing a standard full clearance, or conducting another study. Throughout the summer and fall, near-daily meetings between agency and company personnel, often held by phone, were described internally as a "working group" of sorts to sift through and analyze data, according to the person. Biogen announced in October 2019 that it was reviving the program, but big trials sponsored by the company have produced conflicting results as to whether the drug can slow cognitive decline. One showed no effect and the other showed a very modest benefit. Last November, a committee of FDA advisers voted nearly unanimously against the drug. But in June, Aduhelm received an accelerated approval on the basis of its ability to remove a bad protein called amyloid from the brain. Biogen will still have to conduct another study to prove that the drug slows cognitive decline, but it can sell the drug in the meantime. The agency hadn't discussed publicly the possibility of an accelerated approval prior to its decision. The relationship between amyloid and cognitive decline is anything but clear-cut. Following the approval, three members of the advisory committee quit in protest. [link] [comments]  | ||
| Posted: 09 Jul 2021 07:18 PM PDT
 | ||
| Steve Cohen’s Bet on Melvin Leaves Point72 Trailing Hedge-Fund Peers Posted: 09 Jul 2021 01:16 PM PDT https://finance.yahoo.com/news/steve-cohen-bet-melvin-leaves-192937089.html Katherine Burton, Hema Parmar and Nishant Kumar Fri, July 9, 2021, 3:29 PM (Bloomberg) -- Steve Cohen's Point72 Asset Management barely made money in the first half of 2021, weighed down in part by a wager the billionaire made on Gabe Plotkin, one of his former star traders. The $22 billion Point72 returned just 1.2% in the first six months of the year, lagging behind other large multi-strategy hedge funds such as Citadel, which was up 4.4%, and Millennium Management, which gained 6.5%. Cohen's longtime investment in Plotkin's Melvin Capital Management lost Point72 roughly $500 million this year through June, mostly due to a Reddit-fueled short squeeze in January that cut Melvin's assets by more than half that month. During the height of the meme-stock mania in late January, Cohen invested another $750 million in Melvin. At the same time, Citadel founder Ken Griffin and his firm's partners and hedge funds ponied up $2 billion. That investment is down about 3%, according to a person familiar with transaction. Even with this year's losses, Plotkin has been a profitable trade for Cohen. Point72 invested $200 million in Melvin when he started in 2014, and that sum grew to about $1 billion by the end of 2020 as Plotkin posted multiple years of double-digit returns. Point72 had other issues this year beyond Melvin's struggles. The firm, like many generalist equity funds, got whipped around as value stocks surged on the back of the post-pandemic recovery, only to be overtaken yet again by technology shares and other growth companies that have dominated the market for years. That fake-out was particularly painful for value investor David Einhorn, who has been insisting that beaten down shares were set to soar. His Greenlight Capital plunged 7.6% in June, for a first-half loss of 3%. The fund is down a cumulative 32% since the end of 2014. Some other hedge-fund managers who trade equities had similar struggles in 2021. Andreas Halvorsen's Viking Global Investors returned just 1% this year. Dan Sundheim's D1 Capital Partners, which also got swept up by the skyrocketing price of meme-stock shares in January, is up about 4%, compared with a gain of more than 50% in 2020. Other takeaways from hedge funds' first-half returns: Macro investors also had trouble navigating the market's twists and turns. The benchmark 10-year U.S. Treasury yield unexpectedly jumped 83 basis points in the first quarter, the most since 2016, only to tumble by 27 basis points in the next three months. Brevan Howard Asset Management, which posted a 27% return in its master fund in 2020, the biggest gain in 17 years, is barely even so far in 2021.The growth-value push and pull has also confounded quant funds. The Renaissance Institutional Equities fund is up about 1.1% in the first half, dragged lower by a 4.3% loss in June.Despite the single-digit returns of many large investors, the industry overall saw some of the strongest first-half gains in years. Hedge Fund Research's fund-weighted composite index was up 10% in the first six months of 2021, while its equity index surged 12.7%. A few specialty funds have outperformed. Impala Asset Management, which invests in resource-focused stocks, is up 49% in the first half amid a surge in commodity prices. Glenview Capital Management, which soared 25% in the first quarter thanks to successful wagers on health care stocks, added to its gains in the three months through June, for a total first-half return of 32.5%. Performance figures are according to people familiar with the matter. Representatives for the firms declined to comment. [link] [comments]  | ||
| Posted: 09 Jul 2021 03:13 PM PDT
 | ||
| Posted: 09 Jul 2021 09:26 PM PDT
 | ||
| $XELA, EXELA RANKS #1 for a Potential Short Squeeze! Posted: 09 Jul 2021 09:40 AM PDT
 | ||
| Posted: 09 Jul 2021 08:47 PM PDT
 | ||
| Wall Street Week Ahead for the trading week beginning July 12th, 2021 Posted: 09 Jul 2021 04:12 PM PDT Good Friday evening to all of you here on r/StockMarket. I hope everyone on this sub made out pretty nicely in the market this past week, and is ready for the new trading week ahead. Here is everything you need to know to get you ready for the trading week beginning July 12th, 2021. Earnings season begins in the week ahead with eye-popping growth set to validate market's 2021 run - (Source)
This past week saw the following moves in the S&P:(CLICK HERE FOR THE FULL S&P TREE MAP FOR THE PAST WEEK!)S&P Sectors for this past week:(CLICK HERE FOR THE S&P SECTORS FOR THE PAST WEEK!)Major Indices for this past week:(CLICK HERE FOR THE MAJOR INDICES FOR THE PAST WEEK!)Major Futures Markets as of Friday's close:(CLICK HERE FOR THE MAJOR FUTURES INDICES AS OF FRIDAY!)Economic Calendar for the Week Ahead:(CLICK HERE FOR THE FULL ECONOMIC CALENDAR FOR THE WEEK AHEAD!)Percentage Changes for the Major Indices, WTD, MTD, QTD, YTD as of Friday's close:(CLICK HERE FOR THE CHART!)S&P Sectors for the Past Week:(CLICK HERE FOR THE CHART!)Major Indices Pullback/Correction Levels as of Friday's close:(CLICK HERE FOR THE CHART!)Major Indices Rally Levels as of Friday's close:(CLICK HERE FOR THE CHART!)Most Anticipated Earnings Releases for this week:([CLICK HERE FOR THE CHART!]())(T.B.A. THIS WEEKEND.) Here are the upcoming IPO's for this week:(CLICK HERE FOR THE CHART!)Friday's Stock Analyst Upgrades & Downgrades:(CLICK HERE FOR THE CHART LINK #1!)(CLICK HERE FOR THE CHART LINK #2!)
STOCK MARKET VIDEO: Stock Market Analysis Video for Week Ending July 9th, 2021(CLICK HERE FOR THE YOUTUBE VIDEO!)STOCK MARKET VIDEO: ShadowTrader Video Weekly 7.11.21([CLICK HERE FOR THE YOUTUBE VIDEO!]())(VIDEO NOT YET POSTED!) Here are the most notable companies (tickers) reporting earnings in this upcoming trading week ahead-
([CLICK HERE FOR NEXT WEEK'S MOST NOTABLE EARNINGS RELEASES!]())(T.B.A. THIS WEEKEND.) (CLICK HERE FOR NEXT WEEK'S HIGHEST VOLATILITY EARNINGS RELEASES!)Below are some of the notable companies coming out with earnings releases this upcoming trading week ahead which includes the date/time of release & consensus estimates courtesy of Earnings Whispers:
DISCUSS!What are you all watching for in this upcoming trading week? I hope you all have a wonderful weekendand a great trading week ahead r/StockMarket! [link] [comments]  |
![Assault on Monopolies [Implications for FAANG]](https://external-preview.redd.it/aGIOGzeUUOjNVSZQ8hIjyWx6sKWDB3WyXhzFVKoFvAU.jpg?width=640&crop=smart&auto=webp&s=dbf8dd3c82aa944ad9f25bdb4f952d8114fef98e "Assault on Monopolies [Implications for FAANG]")
![[link]](https://i.redd.it/66uoz26sq7a71.jpg){kind=link}
![[link]](https://i.redd.it/zbipqfz4maa71.jpg){kind=link}
![[link]](https://i.redd.it/vwtzkfa6hba71.jpg){kind=link}
![[link]](https://i.redd.it/s1icciodbaa71.jpg){kind=link}
![[link]](https://i.redd.it/i6u60ick79a71.jpg){kind=link}
![[link]](https://i.redd.it/67701qe5qba71.jpg){kind=link}
![[link]](https://i.imgur.com/Q3ZJWYe.jpg){kind=link}
![[link]](https://i.redd.it/wlmihtxnkba71.png){kind=link}
![[link]](https://i.redd.it/bkzxl1r3fba71.jpg){kind=link}
![[link]](https://i.redd.it/fmzejdnfm5a71.jpg){kind=link}
![[link]](https://i.redd.it/rdb4v233q7a71.png){kind=link}
![[link]](https://i.redd.it/sqe7fevroaa71.png){kind=link}
![[link]](https://i.redd.it/ognx7frqbba71.jpg){kind=link}
![[link]](https://i.redd.it/tf52zo3ot7a71.png){kind=link}
| You are subscribed to email updates from r/StockMarket - Reddit's Front Page of the Stock Market. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment